Exchange: NASDAQ·Updated 07:30 PM EST
AVBP logo

AVBP ArriVent BioPharma Inc.

$10.52
$0.74
(6.57%)
Today
Closed $10.52
$0.00
(0.00%)
After Hours
Reported EarningsNov 9
Mkt Cap$544.13M
Vol1.05M

About AVBP

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.
51

Neutral Sentiment

How do you feel about AVBP?

BiotechSwings
First ADC out of the gate for $AVBP and it did not whisper ARR 217 in GI cancers, 44.8 percent response at 6 mg per kg in late line colorectal patients, 123 treated, generally well tolerated premarket popped about 9 percent and now it moves into Phase 1b dose optimization with 2027 data next
1
filecrux
$AVBP ARR-217 shows a 44.8% response rate at the 6 mg/kg colorectal dose, but only 7 of 13 are confirmed. 🏢 ArriVent BioPharma is a clinical-stage cancer drug developer whose lead drug firmonertinib missed the main goal of its Phase 3 FURVENT trial, per its Oct. 6, 2026 8-K, though firmonertinib is still in a second Phase 3 trial (ALPACCA) 📈 The case against the bear read is that most responders were still on treatment at the cutoff, no one died from treatment, no lung inflammation (ILD) was seen, and grade 3+ drug-related side effects were 20.4% at 6 mg/kg against 30.1% across all 123 patients 📅 Next: Webinar on Monday, October 26, 2026, at 8 am ET, with Phase 1b at 5 and 6 mg/kg and dose optimization data expected in 2027 Source: GlobeNewswire release, Oct 25 + SEC 8-Ks
1
shoc24
$AVBP reported earnings after the close today. GAAP EPS beat estimates: -$0.81 vs. -$1.05 expected, according to Stock Meadow.
filecrux
$AVBP We did a deep dive on ArriVent BioPharma. 🏢 ArriVent BioPharma is a cancer drug developer with no sales whose lead lung drug missed its main Phase 3 goal on October 6, 2026, putting more weight on its colorectal drug ARR-217 ⚠️ ARR-217's 44.8% response rate at 6 mg/kg falls to 24.1% counting only the 7 of 13 confirmed responses, and would reach only 37.9% even if all 4 pending ones hold 📉 The stock fell 28.8% to $14.96 by mid-morning on October 26, below its $15.12 close on the day the lung trial failed ⚠️ About $229.1 million of at-the-market share sales were left at June 30, so selling new stock at low prices is a real dilution risk while the lead drug's path is undecided 📈 The bull read is that 93.1% at 6 mg/kg had their disease held in check, most responders were still on treatment, and severe side effects were 20.4% at that dose against 30.1% overall Full report linked in the replies.
AlertsAndNews
$AVBP ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 "44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program"

Advertisement|Remove ads.